Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.
Daoudlarian D, Segot A, Latifyan S, Bartolini R, Joo V, Mederos N, Bouchaab H, Demicheli R, Abdelhamid K, Ferahta N, Doms J, Stalder G, Noto A, Mencarelli L, Mosimann V, Berthold D, Stravodimou A, Sartori C, Shabafrouz K, Thompson JA, Wang Y, Peters S, Pantaleo G, Obeid M. Daoudlarian D, et al. Among authors: latifyan s. Ann Oncol. 2024 Dec 17:S0923-7534(24)04979-2. doi: 10.1016/j.annonc.2024.12.004. Online ahead of print. Ann Oncol. 2024. PMID: 39701282 Free article.
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J; CheckMate 067 Investigators. Wolchok JD, et al. N Engl J Med. 2025 Jan 2;392(1):11-22. doi: 10.1056/NEJMoa2407417. Epub 2024 Sep 15. N Engl J Med. 2025. PMID: 39282897 Clinical Trial.
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.
Chiffelle J, Barras D, Pétremand R, Orcurto A, Bobisse S, Arnaud M, Auger A, Rodrigo BN, Ghisoni E, Sauvage C, Saugy D, Michel A, Murgues B, Fahr N, Imbimbo M, Ochoa de Olza M, Latifyan S, Crespo I, Benedetti F, Genolet R, Queiroz L, Schmidt J, Homicsko K, Zimmermann S, Michielin O, Bassani-Sternberg M, Kandalaft LE, Dafni U, Corria-Osorio J, Trueb L, Dangaj Laniti D, Harari A, Coukos G. Chiffelle J, et al. Among authors: latifyan s. Immunity. 2024 Oct 8;57(10):2466-2482.e12. doi: 10.1016/j.immuni.2024.08.014. Epub 2024 Sep 13. Immunity. 2024. PMID: 39276771
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study.
Petit PF, Daoudlarian D, Latifyan S, Bouchaab H, Mederos N, Doms J, Abdelhamid K, Ferahta N, Mencarelli L, Joo V, Bartolini R, Stravodimou A, Shabafrouz K, Pantaleo G, Peters S, Obeid M. Petit PF, et al. Among authors: latifyan s. Ann Oncol. 2025 Jan;36(1):43-53. doi: 10.1016/j.annonc.2024.08.2340. Epub 2024 Sep 5. Ann Oncol. 2025. PMID: 39241964 Free article.
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
Joo V, Abdelhamid K, Noto A, Latifyan S, Martina F, Daoudlarian D, De Micheli R, Pruijm M, Peters S, Hullin R, Gaide O, Pantaleo G, Obeid M. Joo V, et al. Among authors: latifyan s. Nat Commun. 2024 Apr 30;15(1):3664. doi: 10.1038/s41467-024-47965-3. Nat Commun. 2024. PMID: 38693123 Free PMC article.
[Oncology: what's new in 2023].
Jankovic J, Abdelhamid K, Berthold D, Desbaillets N, Bouchaab H, Dei Tos G, Demicheli R, Diciolla A, Digklia A, Ferraro DA, Florez L, Galli-Vareia I, Hottinger A, Latifyan S, Liapi A, Mederos N, Giacomuzzi Moore B, Sakr R, Stamatiou A, Wagner AD, Peters S, Sarivalasis A, Vanniere F, Zaman K, Stravodimou A. Jankovic J, et al. Among authors: latifyan s. Rev Med Suisse. 2024 Jan 17;20(856-7):80-87. doi: 10.53738/REVMED.2024.20.856-7.80. Rev Med Suisse. 2024. PMID: 38231107 French.
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
Vicino A, Hottinger AF, Latifyan S, Boughdad S, Becce F, Prior JO, Kuntzer T, Brouland JP, Dunet V, Obeid M, Théaudin M. Vicino A, et al. Among authors: latifyan s. J Neurol. 2024 Apr;271(4):1947-1958. doi: 10.1007/s00415-023-12134-x. Epub 2023 Dec 23. J Neurol. 2024. PMID: 38141128 Free PMC article. Review.
Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial.
da Silva Lopes AM, Colomer-Lahiguera S, Darnac C, Giacomini S, Bugeia S, Gutknecht G, Spurrier-Bernard G, Cuendet M, Muet F, Aedo-Lopez V, Mederos N, Michielin O, Addeo A, Latifyan S, Eicher M. da Silva Lopes AM, et al. Among authors: latifyan s. JMIR Res Protoc. 2023 Oct 18;12:e48386. doi: 10.2196/48386. JMIR Res Protoc. 2023. PMID: 37851498 Free PMC article.
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors.
da Silva Lopes AM, Colomer-Lahiguera S, Darnac C, Giacomini S, Bugeia S, Gutknecht G, Spurrier-Bernard G, Aedo-Lopez V, Mederos N, Latifyan S, Addedo A, Michielin O, Eicher M. da Silva Lopes AM, et al. Among authors: latifyan s. Support Care Cancer. 2023 Jul 22;31(8):484. doi: 10.1007/s00520-023-07934-w. Support Care Cancer. 2023. PMID: 37480546 Free PMC article. Clinical Trial.
36 results